The interaction between aspirin and losartan on cardiovascular morbidity and mortality in patients with hypertension and left ventricular hypertrophy. A losartan intervention for endpoint reduction (LIFE) substudy

被引：0
|
作者：
Fossum, E
Kjeldsen, SE
Dahlof, B
Devereux, RB
Julius, S
Snapinn, S
机构：
[1] Ullevaal Univ Hosp, Dept Cardiol, Oslo, Norway
[2] Sahlgrens Univ Hosp, Dept Med, S-41345 Gothenburg, Sweden
[3] Cornell Med Ctr, Div Cardiol, New York, NY USA
[4] Univ Michigan, Dept Internal Med, Div Hypertens, Ann Arbor, MI 48109 USA
[5] Merck & Co Inc, Whitehouse Stn, NJ USA
来源：
AMERICAN JOURNAL OF HYPERTENSION | 2003年 / 16卷 / 05期
关键词：
losartan; aspirin; atenolol;
D O I：
10.1016/S0895-7061(03)00111-0
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
OR27
引用
收藏
页码：11A / 12A
页数：2
相关论文
共 50 条
  • [21] Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients -: The Losartan Intervention for Endpoint reduction (LIFE) in hypertension study
    Okin, PM
    Devereux, RB
    Jern, S
    Kjeldsen, SE
    Julius, S
    Dahlöf, B
    HYPERTENSION, 2000, 36 (05) : 766 - 773
  • [22] Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol
    Lindholm, LH
    Ibsen, H
    Dahlöf, B
    Devereux, RB
    Beevers, G
    de Faire, U
    Fyhrquist, F
    Julius, S
    Kjeldsen, SE
    Kristiansson, K
    Lederballe-Pedersen, O
    Nieminen, MS
    Omvik, P
    Oparil, S
    Wedel, H
    Aurup, P
    Edelman, J
    Snapinn, S
    LANCET, 2002, 359 (9311): : 1004 - 1010
  • [23] QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy -: The Losartan Intervention for Endpoint Reduction in Hypertension study
    Oikarinen, L
    Nieminen, MS
    Viitasalo, M
    Toivonen, L
    Jern, S
    Dahlöf, B
    Devereux, RB
    Okin, PM
    HYPERTENSION, 2004, 43 (05) : 1029 - 1034
  • [24] Losartan for LIFE in hypertension with left ventricular hypertrophy?
    Doggrell, SA
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (01) : 115 - 118
  • [25] Cardiovascular morbidity and mortality in patients without pre-existing vascular disease in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE)
    Devereux, RB
    Dahlof, B
    Kjeldsen, SE
    Julius, S
    Aurup, P
    Beevers, G
    Edelman, J
    de Faire, U
    Fyhrquist, F
    Harris, K
    Ibsen, H
    Kristiansson, K
    Lederballe-Pedersen, O
    Lindholm, LH
    Nieminen, MS
    Omvik, P
    Oparil, S
    Snappin, S
    Wedel, H
    CIRCULATION, 2002, 106 (19) : 475 - 476
  • [26] Losartan-based versus atenolol-based therapy in patients with hypertension and left ventricular hypertrophy: An economic evaluation of the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study for Germany
    Krobot, K. J.
    Carides, G. W.
    Wagner, A.
    Burke, T. A.
    VALUE IN HEALTH, 2006, 9 (06) : A353 - A353
  • [27] Effect of losartan compared to atenolol on cardiovascular mortality and morbidity in high and low risk patients with hypertension and left ventricular hypertrophy - The LIFE study
    Franklin, S
    Wachtell, K
    Papademetriou, V
    Olsen, MH
    Fyhrquist, F
    Ibsen, H
    Julius, S
    Kjeldsen, S
    Dahlof, B
    CIRCULATION, 2003, 108 (17) : 764 - 764
  • [28] Female sex and effect of Losartan versus atenolol in patients with hypertension and left ventricular hypertrophy. The LIFE study
    Os, I
    Oparil, S
    Kjeldsen, SE
    Gerdts, E
    Hille, DA
    Lyle, PA
    Fouad-Tarazi, F
    Dahlof, B
    Devereuz, RB
    Julius, S
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (03) : 374A - 374A
  • [29] Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
    McInnes, G
    Burke, TA
    Carides, G
    JOURNAL OF HUMAN HYPERTENSION, 2006, 20 (01) : 51 - 58
  • [30] Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
    G McInnes
    T A Burke
    G Carides
    Journal of Human Hypertension, 2006, 20 : 51 - 58
12345